Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015-12-11
|
| gptkbp:approvedBy |
gptkb:PMDA
gptkb:FDA gptkb:EMA |
| gptkbp:ATCCode |
L01XE36
|
| gptkbp:brand |
gptkb:Alecensa
|
| gptkbp:CASNumber |
1256580-46-7
|
| gptkbp:chemicalFormula |
C30H34N4O2
|
| gptkbp:genericName |
gptkb:alectinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alecensa
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
ALK inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
edema constipation fatigue myalgia |
| gptkbp:target |
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:alectinib
gptkb:Roche gptkb:Chugai_Pharmaceutical |
| gptkbp:bfsLayer |
6
|